StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Early-stage safety improves; OS-like signals in a hard-to-treat population could attract investor attention and potential upside if corroborated by additional cohorts.
What happened, with direct paths to the underlying reporting
Anixa announced the first patient in Cohort 5 was dosed at the highest level (1x10^7 CAR-positive cells/kg) in its FSHR-targeted CAR-T trial for recurrent ovarian cancer at Moffitt. With no dose-limiting toxicities and five patients surviving over a year (one beyond two years), the data offer an early but meaningful safety/efficacy signal that could accelerate enrollment and upcoming milestones.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.